annual rate (SE) of decline in FVC over 192 weeks in Asian patients was −127 (11) mL/year. Diarrhoea was the most common adverse event in 
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Background and Aims: The prevalence and incidence of IPF from 1997 to 2007 in Taiwan is 0.7-6.4 cases/100,000 and 0.6-1.4/100,000 respectively, which is relatively low compared to western countries (Raghu, G., et al. Am J Respir Crit Care Med, 2006. 174: P. 810-6.) . The mean survival in Taiwan is only 0.9 year after IPF diagnosis.
There are two anti-fibrotic drugs conditionally recommended in 2015 IPF treatment guidance: Nintedanib and Pirfenidone. Nintedanib (OFEV ® ) is on the market in Taiwan since September 2015 and Pirfenidone (Pirespa ® ) will be on market in the first half of 2017.
Data on characteristics and management of IPF patients are still scarce in Taiwan. An IPF non-intervention study would help to gain a better understanding of the epidemiology of the disease and how it is currently managed.
The objective of this non-interventional study is to characterize the IPF population in Taiwan with regard to their demographic, clinical characteristics and treatment.
Methods: IPF patients will be enrolled in a consecutive manner and data will be collected in accordance with real-world clinical practice (baseline, and planned at 1st month and every 3 months afterward, and visits will be in accordance with clinical needs judged by physicians). The enrolment period for the study will be one year and each patient will be followed-up for 2 years. Background and Aims: Interstitial lung disease (ILD) is the most common pulmonary complication in patients with rheumatoid arthritis (RA). Certain drugs used to treat RA, such as methotrexate or anti-tumor necrosis factor-alpha antibodies, have been associated with the development or progression of ILD. Therefore, drugs used for treating RA with ILD should be administered carefully. This study aimed to evaluate the safety of tocilizumab on ILD in patients with RA.
Results
Methods: Subjects were 12 patients (6 men, 6 women, mean age 74.5 years) with both RA and ILD. Types of ILD were idiopathic pulmonary fibrosis pattern 11 and nonspecific interstitial pneumonia pattern 1. The effect of tocilizumab was evaluated before, 1 month after, and 6 months after administration.
Results: Mean levels of matrix metalloproteinase-3 (MMP-3), which is a biomarker of RA disease activity, were 296 AE 319, 200 AE 266, and 202 AE 270 ng/mL, respectively. Significant differences were observed between before and after administration of tocilizumab (before vs 1 month: P < 0.05, before vs 6 months: P < 0.05). Mean levels of Krebs von den Lungen-6 (KL-6) were 718 AE 323, 720 AE 210, and 594 AE 276 U/mL, respectively. No significant differences were observed between before and after administration. Mean levels of lactate dehydrogenase (LDH) were 236 AE 37, 241 AE 44, and 248 AE 51 U/mL, respectively. No significant differences were observed between before and after administration. Chest computed tomography (CT) revealed no differences between before and 1 year after administration.
Conclusion:
The disease activity of RA was significantly improved by administration of tocilizumab, and ILD did not progress. In patients with both RA and ILD, tocilizumab could be administrated safely without progression of ILD. We have analyzed other markers and will present our final results at the APSR 2018 Congress. 
